188 related articles for article (PubMed ID: 29371290)
1. Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase Inhibitors.
Kostas M; Haugsten EM; Zhen Y; Sørensen V; Szybowska P; Fiorito E; Lorenz S; Jones N; de Souza GA; Wiedlocha A; Wesche J
Mol Cell Proteomics; 2018 May; 17(5):850-870. PubMed ID: 29371290
[TBL] [Abstract][Full Text] [Related]
2. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
3. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
4. A novel type I fibroblast growth factor receptor activates mitogenic signaling in the absence of detectable tyrosine phosphorylation of FRS2.
Lopez ME; Korc M
J Biol Chem; 2000 May; 275(21):15933-9. PubMed ID: 10748122
[TBL] [Abstract][Full Text] [Related]
5. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
6. Protein tyrosine phosphatase receptor type γ is a JAK phosphatase and negatively regulates leukocyte integrin activation.
Mirenda M; Toffali L; Montresor A; Scardoni G; Sorio C; Laudanna C
J Immunol; 2015 Mar; 194(5):2168-79. PubMed ID: 25624455
[TBL] [Abstract][Full Text] [Related]
7. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
[TBL] [Abstract][Full Text] [Related]
8. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
9. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.
Cross MJ; Lu L; Magnusson P; Nyqvist D; Holmqvist K; Welsh M; Claesson-Welsh L
Mol Biol Cell; 2002 Aug; 13(8):2881-93. PubMed ID: 12181353
[TBL] [Abstract][Full Text] [Related]
10. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia.
Della Peruta M; Martinelli G; Moratti E; Pintani D; Vezzalini M; Mafficini A; Grafone T; Iacobucci I; Soverini S; Murineddu M; Vinante F; Tecchio C; Piras G; Gabbas A; Monne M; Sorio C
Cancer Res; 2010 Nov; 70(21):8896-906. PubMed ID: 20959494
[TBL] [Abstract][Full Text] [Related]
11. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
12. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
13. Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.
Shu ST; Sugimoto Y; Liu S; Chang HL; Ye W; Wang LS; Huang YW; Yan P; Lin YC
Anticancer Res; 2010 Jun; 30(6):1937-46. PubMed ID: 20651337
[TBL] [Abstract][Full Text] [Related]
14. Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries.
Hughes SE
Cardiovasc Res; 1996 Sep; 32(3):557-69. PubMed ID: 8881516
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
16. Direct cell cycle regulation by the fibroblast growth factor receptor (FGFR) kinase through phosphorylation-dependent release of Cks1 from FGFR substrate 2.
Zhang Y; Lin Y; Bowles C; Wang F
J Biol Chem; 2004 Dec; 279(53):55348-54. PubMed ID: 15513912
[TBL] [Abstract][Full Text] [Related]
17. Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes.
Rajendran R; Böttiger G; Dentzien N; Rajendran V; Sharifi B; Ergün S; Stadelmann C; Karnati S; Berghoff M
Cells; 2021 May; 10(6):. PubMed ID: 34070622
[TBL] [Abstract][Full Text] [Related]
18. NCAM-mimetic, FGL peptide, restores disrupted fibroblast growth factor receptor (FGFR) phosphorylation and FGFR mediated signaling in neural cell adhesion molecule (NCAM)-deficient mice.
Aonurm-Helm A; Berezin V; Bock E; Zharkovsky A
Brain Res; 2010 Jan; 1309():1-8. PubMed ID: 19909731
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.
Weeden CE; Holik AZ; Young RJ; Ma SB; Garnier JM; Fox SB; Antippa P; Irving LB; Steinfort DP; Wright GM; Russell PA; Ritchie ME; Burns CJ; Solomon B; Asselin-Labat ML
Mol Cancer Ther; 2017 Aug; 16(8):1610-1622. PubMed ID: 28611104
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
